In human ARDS patients, treatment with recombinant MIF augmented proinflammatory cytokine secretion and an anti-MIF antibody treatment attenuated proinflammatory response, which suggests the role of MIF as a mediator of pulmonary inflammation [81]. The gene discussed is MIF; the disease is acute respiratory distress syndrome.